CORE--DEVELOPMENTAL SUPPORT

AECOM CFAR打算继续利用发展资金， 招募两名艾滋病研究新手，他们以前没有 在这一领域获得了相当于单个RO1的支持。 第六年， 第一优先权将给予分子或细胞免疫学家， 疫苗研发的专业知识。 将提供最多 两年 征聘机制将仿照 在CFAR和AECOM癌症中已经进行了类似的努力 研究中心和肝脏研究中心。 该职位也将是 在科学期刊上刊登广告，并为促进招聘 少数民族考生，将写信给研究生院， 重点关注少数民族项目。申请将由博士审查。 并提交指导委员会和IAC批准。 来自机构内部和外部的潜在新研究者 将根据指导委员会的建议进行评估和选择 委员会，内部（IAC）和外部咨询委员会（IAC）。 我们将继续每年支持一个AECOM的可行性研究 调查员，准备制定申请， 审查支持。 最后，将为两个不断发展的研究机会预留资金 在AECOM调查员中。 这种支持将限于六个月 以解决不断出现的需要快速解决的关键想法。 将鼓励涉及基础和临床的申请 研究合作。

The AECOM CFAR intends to continue to utilize developmental funds to recruit two investigators new to AIDS research, who have not previously received individual RO1 equivalent support in this field. In year 6 the first priority will be given to a molecular or cellular immunologist with expertise in vaccine development. Funding will be provided for a maximum of two years. Mechanisms of recruitment will be modelled after comparable efforts already in place in the CFAR, and the AECOM Cancer Research Center and Liver Research Center. The position will also be advertised in scientific journals and, to facilitate recruitment of minority candidates, letters will be written to graduate schools with a major focus on minority programs. Applications will be reviewed by Dr. Lilly and submitted for approval of the Steering Committee and the IAC. Potential new investigators from within the institution and from outside will be evaluated and selected based on recommendations of the Steering Committee, Internal (IAC) and External Advisory (IAC) Committee. We will continue yearly support for one feasibility study by an AECOM investigator, preparatory to the development of an application for prior reviewed support. Finally, funds will be set aside for two evolving research opportunities among AECOM investigators. This support will be limited to six months to address arising critical ideas that demand rapid solution. Encouragement will be given to applications entailing basic and clinical research collaboration.